News

Seattle Children's Innovating Immunotherapy to Help Treatment Last Longer

Seattle Children's Innovating Immunotherapy to Help Treatment Last Longer

Doctors at the Ben Towne Center for Childhood Cancer Research take T-cells from a patient and modify them to target cancer cells. Dr. Colleen Annesley, an oncologist at Seattle Children’s and lead investigator of the latest immunotherapy trial called PLAT-03, said the first study, PLAT-02, had a 93 percent success rate, but about half of those children experienced a recurrence of their cancer. With this new trial, they hope to improve those odds.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.